Association Between LRG and Histologic Remission in Ulcerative Colitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-90
SponsorShowa Inan General Hospital
About this trial
We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed annually, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
definitive UC patients based on the standard criteria
Disqualifiers
None
Trial population
definitive UC patients based on the standard criteria for UC
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Histologic remission of UC
Histologic remission is defined as \< grade 2 using Geboes score.
Time frame
1 weekSecondary outcomes
1
Endoscopic remission
Endoscopic remission is defined as score 0 using the Mayo endoscopic subscore.
Time frame
1 weekSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov